Uptake and continuation of HIV pre-exposure prophylaxis among women of reproductive age in two health facilities in Kisumu County, Kenya.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
03 2023
Historique:
received: 14 05 2022
accepted: 08 02 2023
entrez: 13 3 2023
pubmed: 14 3 2023
medline: 15 3 2023
Statut: ppublish

Résumé

In 2020, Kenya had 19,000 new HIV infections among women aged 15+ years. Studies have shown sub-optimal oral pre-exposure prophylaxis (PrEP) use among sub-populations of women. We assessed the uptake and continuation of oral PrEP among women 15-49 years in two health facilities in Kisumu County, Kenya. A retrospective cohort of 262 women aged 15-49 years, initiated into oral PrEP between 12 November 2019 and 31 March 2021, was identified from two health facilities in the urban setting of Kisumu County, Kenya. Data on baseline characteristics and oral PrEP continuation at months 1, 3 and 6 were abstracted from patient records and summarized using descriptive statistics. Missing data in the predictor variables were imputed within the joint modelling multiple imputation framework. Using logistic regression, we evaluated factors associated with the discontinuation of oral PrEP at month 1. Of the 66,054 women screened, 320 (0.5%) were eligible and 262 (82%) were initiated on oral PrEP. Uptake was higher among women 25-29 years as compared to those 15-24 years (77% vs. 33%). Oral PrEP continuation declined significantly with increasing duration of follow-up; 37% at month 1, 21% at month 3 and 12% at month 6 (p<0.05). In the adjusted analysis, women 15-24 years had lower adjusted odds of continuing at month 1 than women ≥25 years (adjusted odds ratio [aOR]: 0.41, 95% CI: 0.21-0.82). There was no association between being sero-discordant and continuation of oral PrEP at month 1 (aOR; 1.21, 95% CI 0.59-2.50). Women from the sub-county hospital were more likely to continue at month 1 of follow-up compared to women enrolled in the county referral hospital (aOR 5.11; 95% CI 2.24-11.70). The low eligibility for oral PrEP observed among women 15-49 years in an urban setting with high HIV prevalence calls for a review of the screening process to validate the sensitivity of the screening tool and its proper application. The low uptake and continuation among adolescent girls and young women underscores the need to identify and address specific patient- and facility-level barriers affecting different sub-populations at risk for HIV acquisition.

Identifiants

pubmed: 36912204
doi: 10.1002/jia2.26069
pmc: PMC10009800
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e26069

Subventions

Organisme : NIMH NIH HHS
ID : P30 MH062246
Pays : United States
Organisme : CGH CDC HHS
ID : NU2GGH001947
Pays : United States
Organisme : PEPFAR
Pays : United States

Informations de copyright

© 2023 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

J Infect Dis. 2016 Jul 1;214(1):55-64
pubmed: 26917574
J Int AIDS Soc. 2018 Nov;21(11):e25208
pubmed: 31291057
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
J Clin Epidemiol. 2019 Jun;110:63-73
pubmed: 30878639
Lancet. 2012 Apr 28;379(9826):1641-52
pubmed: 22538179
J Acquir Immune Defic Syndr. 2021 May 1;87(1):e150-e158
pubmed: 33492024
Curr Opin HIV AIDS. 2016 Jan;11(1):18-26
pubmed: 26417954
Int J STD AIDS. 2020 Oct;31(11):1063-1072
pubmed: 32819210
Lancet. 2016 Jan 2;387(10013):53-60
pubmed: 26364263
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
PLoS One. 2020 Jan 13;15(1):e0226062
pubmed: 31929547
PLoS Med. 2017 Nov 21;14(11):e1002444
pubmed: 29161256
Lancet HIV. 2020 Apr;7(4):e249-e261
pubmed: 32087152
Source Code Biol Med. 2008 Dec 16;3:17
pubmed: 19087314
Int J Clin Pharm. 2014 Feb;36(1):70-85
pubmed: 24129582
PLoS One. 2021 Oct 14;16(10):e0258542
pubmed: 34648589
AIDS. 2016 Jul 31;30(12):1973-83
pubmed: 27149090

Auteurs

Mercelline Ogolla (M)

Afya Bora Consortium, Department of Global Health, University of Washington, Seattle, Washington, USA.

Omoto Lennah Nyabiage (OL)

Division of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.

Paul Musingila (P)

Division of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.

Susan Gachau (S)

Division of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.

Theresa M A Odero (TMA)

Afya Bora Consortium, Department of Global Health, University of Washington, Seattle, Washington, USA.

Elijah Odoyo-June (E)

Division of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.

Boniface Ochanda (B)

Division of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.

Aoko Appolonia (A)

Division of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.

Elizabeth Katiku (E)

Division of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.

Rachael Joseph (R)

Division of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.

Cirrilus Ogolla (C)

Center for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya.

Linda Otieno (L)

Center for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya.

Francesca Odhiambo (F)

Center for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya.

Hong-Ha M Truong (HM)

Department of Medicine, University of California San Francisco, San Francisco, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH